
Opinion|Videos|October 10, 2017
Choosing Second-Line Therapy for Patients With Urothelial Carcinoma
Author(s)Sumanta Kumar Pal, MD
Sumanta K. Pal, MD, medical oncologist, assistant clinical professor, Department of Medical Oncology and Therapeutics Research, City of Hope, discusses choosing second-line therapy for patients with urothelial carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Long-Term OMNIVORE Data Show Durable Treatment-Free Survival in RCC
2
Phase 3 ENHANCE Trial: Magrolimab Adds Toxicity, Not Benefit, in MDS
3
Advanced Renal Cell Carcinoma: Summarizing a Practical First-Line Treatment Algorithm
4
First Patients Dosed With TLX597-Tx in Trial for mHSPC
5
































